Merck KGaA (OTCMKTS:MKKGY) Rating Lowered to “Hold” at UBS Group

Merck KGaA (OTCMKTS:MKKGY) was downgraded by analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

MKKGY has been the topic of a number of other research reports. Jefferies Financial Group assumed coverage on Merck KGaA in a research report on Tuesday, May 26th. They set a “hold” rating on the stock. HSBC upgraded Merck KGaA to a “hold” rating in a research note on Monday, July 6th. Finally, Zacks Research raised Merck KGaA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 22nd. Six equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, Merck KGaA has a consensus rating of “Hold”.

Merck KGaA Stock Up 0.6%

Shares of MKKGY stock opened at $32.24 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.00 and a current ratio of 1.51. The firm’s 50-day moving average is $32.23 and its 200-day moving average is $29.36. The stock has a market cap of $20.83 billion, a price-to-earnings ratio of 16.62, a PEG ratio of 2.62 and a beta of 0.98. Merck KGaA has a 52-week low of $23.73 and a 52-week high of $34.19.

Merck KGaA Company Profile

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.